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ABSTRACT 
 
Objective: Our aim was to find out how Cochrane reviews of five popular or 
frequently prescribed second-generation antipsychotics (SGAs) in the UK 
(olanzapine, risperidone, quetiapine, amisulpride and aripiprazole) approached the 
problem of high drop-out in placebo-controlled trials.  
 
Method: We examined the following: (1) whether reviews included data from 
studies with a level of drop-out exceeding their stated exclusion criterion; (2) the 
level of missing data each efficacy outcome in each review relied upon (3) impact 
of excluding studies with high drop-out.  
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Results: All reviews included data they stated they would exclude because of 
unacceptable levels of attrition, four (risperidone, olanzapine, amisulpride, 
aripiprazole) without clear acknowledgement or justification. Several reviews also 
excluded data from a number of relatively low-attrition studies because of missing 
standard deviations.  
 
Conclusion: Cochrane reviews of five popular antipsychotics for schizophrenia 
misrepresented the available evidence on their efficacy. The impact of including 
high-attrition studies was difficult to quantify because of the exclusion of relevant 
low-attrition studies. Further analysis of the efficacy of these drugs in studies with 
acceptable rates of attrition is required. To reduce the problem of high attrition, 
trialists should gather follow-up data from people who leave the double-blind 
process early. 
 
Key words: Antipsychotics, randomised controlled trial, meta-analysis,  
schizophrenia. 
 
(Word count 4,342) 
 
Summations:  Currently available Cochrane reviews of five popular 
antipsychotics for schizophrenia included studies they 
stated they would exclude because of high levels of 
attrition, thus misrepresenting the evidence supporting their 
efficacy. 
 
The impact of including high-attrition studies was difficult to 
quantify because of the exclusion of important low-attrition 
studies due to missing standard deviations. Further 
analysis of the efficacy of these drugs in studies with 
acceptable rates of attrition is required. 
 
Cochrane reviews of antipsychotics are severely limited by 
limited reporting of data, very high attrition and lack of 
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follow-up by trial researchers. 
 
Considerations: New low attrition studies have been published since most of 
these reviews were completed. 
 
This review has not looked at comparisons of second-
generation antipsychotics (SGAs) with other antipsychotics 
or examined the adverse effects of each SGA. The SGAs 
included here are generally accepted to be at least 
equivalent to first-generation drugs - both in terms of 
efficacy and tolerability. 
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INTRODUCTION 
 
Antipsychotic medication is currently regarded as the cornerstone of treatment for 
people with a diagnosis of schizophrenia. Second-generation antipsychotics 
(SGAs) were thought to be more effective than first-generation antipsychotics 
(FGAs) with less extra-pyramidal adverse effects. However, with the exception of 
clozapine, their superiority is increasingly under question (1). SGAs are frequently 
prescribed and are continually gaining in popularity in the UK (2) and across the 
world (3). 
 
The clinical evidence for the efficacy of most SGAs has been the subject of several 
published Cochrane systematic reviews. Cochrane reviews are independent, 
updated regularly and highly regarded in medicine and healthcare. They have 
greater methodological rigour in comparison to non-Cochrane reviews (4), are 
much less prone to bias (5, 6) and have a considerable impact on the health policy 
of many countries (7). They consist of two peer-reviewed publications; a protocol 
and the review. The protocol specifies the topic, scope and methods used and the 
review reports the results of the search and efficacy analysis. The publication of 
protocols reduces the risk of important decisions being made after the review 
authors have seen the data, thus minimising the risk of author bias (for discussion, 
see section 2.1 of the Cochrane Handbook; 8). Deviations from the protocol are 
discouraged, although recognised as sometimes necessary. The current Handbook 
strongly encourages documentation of any changes as well as sensitivity analyses 
to explore their impact (8).  
  
Our aim in this paper was to find out how current Cochrane reviews of the 5 most 
popular second-generation antipsychotics (SGAs) in the UK approached the 
problem of high drop-out in placebo-controlled SGA trials. 
 
The importance of attrition 
 
Attrition is a particular focus of this review because it is generally unacceptably 
high in antipsychotic medication trials, particularly when a placebo arm is included 
(9). High attrition is difficult to deal with statistically when there is evidence that 
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data missing for non-random reasons, as could be the case for antipsychotic trials 
(10). Improper management of missing data can result in non-equivalent treatment 
groups and biased estimates of treatment effect (11, 12). 
 
Although a recent meta-analysis found a moderate superiority of atypical 
antipsychotics over placebo (13), around half of the 38 included studies were 
missing over half their outcome data. The authors argued it is unclear what degree 
of attrition will bias results (cf. 14). However medical epidemiologists and 
CONSORT statement authors Kenneth Schulz and David Grimes, writing in The 
Lancet in 2002, stated: “a trial would be unlikely to successfully withstand 
challenges to its validity with losses of more than 20% [Sackett et al., 2000].” (15).  
 
If the opinions of Schulz and Grimes (15) and Sackett and colleagues (16) reflect 
generally accepted standards in evidence-based medicine, then serious doubts 
must be raised about the findings of systematic reviews of antipsychotic medication 
when almost all of the included trials have greater than 20% attrition (e.g., 13). 
Supporting this, a recent survey by the Cochrane Schizophrenia Group found 
psychiatrists, psychiatric researchers and carers agreed that results from trials lack 
credibility if they suffer from more than 25% attrition over 12 weeks (17).  
 
Aims of the Study 
 
The goals of this review were to find out how Cochrane reviews comparing popular 
SGAs to placebo dealt with the issue of attrition and whether excluding high-
attrition studies would affect their results.  
 
Material and methods 
 
The four most frequently prescribed SGAs in the UK are, from most to least 
popular, olanzapine, risperidone, quetiapine and amisulpride (2). The Cochrane 
review of aripiprazole was also included given its rising popularity with psychiatrists 
and pharmacists (18).  
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The five relevant Cochrane reviews (19-23) were downloaded from the Cochrane 
website by the first author in April 2010. Only the efficacy outcomes in SGA versus 
placebo comparisons were examined. The following information was gathered: 
 
Acceptable level of attrition: The level of attrition from a study outcome each review 
stated they would exclude (or intended to exclude). 
Included studies: Whether each review only included data from studies which met 
their stated attrition cut-off criterion.  
Acknowledgment of violation of exclusion criterion: Whether a Cochrane review 
which included data from studies they said they would exclude acknowledged this 
clearly in the text and provided a reason. 
Reported findings and missing data: We calculated the proportion of missing data 
each efficacy outcome in each review relied upon. 
Results after excluding outcomes with >50% and >25% attrition: Results after 
excluding data with >50% and >25% attrition were calculated using the same 
software (Revman 5) and statistical assumptions used by Cochrane review  
authors.  
Management of missing data and other methodological concerns: How the review 
authors managed missing data and other methodological issues. 
 
Where information was missing, every effort was made to access the original 
paper(s) or contact the review authors for clarification. All calculations were initially 
performed by PH and independently replicated by PT. 
 
Results 
 
Acceptable level of attrition 
 
The level of attrition judged to be acceptable by Cochrane reviews of different 
SGAs varied between 40% and 50% (Table 1). 
 
Included studies 
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All reviews violated their own predetermined criterion by including data from trials 
they said they would exclude because of the level of attrition.  
 
Olanzapine. The olanzapine authors, who stated (p.5) they would exclude data 
from studies with >50% total attrition, based all their outcomes in the main 
olanzapine vs. placebo comparison on 3 studies with attrition between 58.6%  (24, 
25) and 79% (26).  
 
Risperidone. The risperidone authors, who stated on p.8 they would exclude data 
from studies with >50% total attrition, based 10 outcomes either partially or 
completely on the results of the 6mg and placebo arms of one 8-week study (27) 
with combined attrition of 57%. They also included data from a study which 
reported an N of 24 for the risperidone and placebo arms combined, and zero 
attrition (28). However, according to an internal confidential report by the makers of 
risperidone, Janssen Pharmaceuticals, 107 people were randomised to receive 
risperidone or placebo in this study, 59% of whom left early. This study contributed 
to 2 efficacy outcomes in the review.   
 
Quetiapine. The quetiapine authors stated on p.5 they had intended, before seeing 
the data, to exclude data from studies with >50% attrition. They based 7 of their 8 
efficacy outcomes either entirely or partially on one or more studies with >50% total 
attrition, all lasting 6 weeks.  
 
Amisulpride. The amisulpride authors, who stated (p.5) they would exclude trial 
outcomes with >40% attrition, based 5 out of their 8 outcomes partially on one very 
small 6-week study with 40.7% attrition (29). 
 
Aripiprazole. The aripiprazole authors, who stated on p.5 they would not include 
trial outcomes with >40% total attrition, partially based their aripiprazole vs. 
placebo outcome ‘poor compliance with study protocol’ on data from a 4-week 
study with 41% attrition (30), a 4-week study with 41.8% attrition (31), a 6-week 
study with 46.9% attrition (32), a 4-week study with 52.2% attrition (33) and a 6-
week study with 66.2% attrition (33). The outcome ‘needing additional antipsychotic 
medication’ was partially based on the results of the latter two studies. The 
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treatment arm attrition for one of these studies (30) was lower in the review (18%, 
p.53) than in the original paper (37%). 
 
The aripiprazole authors based their 2 primary outcomes (‘relapse’ over short and 
medium terms) on one study with >50% attrition (34), however withdrawal due to 
deterioration was this trial’s primary outcome measure.  
 
Acknowledgment of breaking exclusion criterion 
 
One review (quetiapine) which broke its exclusion criterion clearly acknowledged 
this and provided a reason. The authors stated they were surprised by the levels of 
attrition once they saw the data and that adherence to their original protocol 
(excluding studies with >50% attrition) would “leave few data to present.” (p.5; 21). 
The olanzapine, risperidone, aripiprazole and amisulpride reviews included data 
they said they would exclude without clear acknowledgement or reason in the main 
text.  
 
Reported findings and attrition 
 
Summarising the results (see Table 1) reveals that 100% of outcomes reported in 
the olanzapine vs. placebo comparison are based on >50% missing data for both 
treatment and placebo groups, 47% (n=8) are based on >60% missing data in both 
groups and one is based on >70% missing data in both groups. 
 
For the quetiapine vs. placebo comparison, 75% of reported outcomes rely on 
>50% missing data for both groups. Almost half of the risperidone outcomes and 
half of the amisulpride outcomes rely on data with >20% attrition in both groups. 
One outcome (needing additional antipsychotics) in the aripiprazole vs. placebo 
comparison relies on data with >40% attrition in both placebo and treatment 
groups. One outcome (poor compliance with study protocol) relies on data with 
attrition >30% in both groups. 
 
Results after excluding outcomes with >50% and >25% attrition  
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Olanzapine. Excluding trial data where >50% and >25% of total follow-up data 
were missing (and excluding a study involving the treatment of clozapine 
discontinuation symptoms (35) eliminated all data in the main olanzapine vs. 
placebo comparison, resulting in an empty review. See Table 1. 
 
Risperidone. There were a number of problems in the risperidone review. The data 
for ‘Marder 1994b’ (36) was entered the wrong way round (erroneously favouring 
placebo) for 2 outcomes (endpoint Brief Psychiatric Rating Scale [BPRS] total 
scores and Positive and Negative Syndrome Scale [PANSS] positive symptom 
scores), a per-protocol analysis was used for the outcome of ‘needing additional 
antipsychotic medication’ instead of intention-to-treat (ITT), data on needing 
concomitant sedatives was incorrectly extracted from ‘Marder 1994b’ (36), Global 
Assessment of Functioning (GAF) scores were misinterpreted as favouring 
risperidone when in fact they favoured placebo, standard errors (SE) were used 
instead of standard deviations (SD) in the analyses of average change in Clinical 
Global Impression - Severity (CGI-S) scores and average change in PANSS scores 
(total, positive and negative scale scores) and a fixed-effect analysis was used 
instead of random effects for the outcome of 20% change in total PANSS/BPRS 
scores. Finally, according to the study publication (37), study NCT00272584 
defined response using PANSS scores not CGI-S ratings, therefore this study 
should not have contributed data to the outcome of ‘no clinically significant 
improvement’.  
 
Fixing these and other problems reduced the number of outcomes which were 
equivocal (from 10 to 9), increased the number favourable to risperidone (from 9 to 
10) but had no effect on the number favourable to placebo (N=2). The previously 
equivocal outcomes of endpoint BPRS total scores and ‘no clinically significant 
improvement’ now favoured risperidone, while the previously drug-favourable 
outcome of mean change in PANSS negative symptoms became equivocal. 
 
Excluding outcomes from the 2 trials with >50% attrition removed all data from one 
outcome (numbers achieving a 20% reduction in BPRS total scores), reduced the 
number of outcomes favouring risperidone from 10 to 9 but had no effect on the 
number of equivocal or placebo-favourable outcomes. Removing data with >25% 
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attrition reduced the number of outcomes favouring risperidone to 4, reduced the 
number of equivocal outcomes to 7 and increased the number of placebo-
favourable outcomes to 6. Three outcomes could not be estimated due to lack of 
data. See Table 2 for details on outcomes and effect sizes. 
 
Quetiapine. Three treatment favourable outcomes in the quetiapine vs. placebo 
comparison survived after excluding studies with >50% total attrition but these 
were all based entirely on the results of one study with 12 participants, lasting 3 
weeks (38). Three outcomes in the original review could no longer be calculated. 
Removing data with >25% attrition from the quetiapine review had exactly the 
same effect on results as removing data with >50% attrition. 
 
Amisulpride. No amisulpride outcomes in the original review were affected by 
excluding data with >50% attrition. Excluding data with >25% attrition resulted in an 
almost empty review. The findings were equivocal for the one remaining outcome 
that could be calculated (needing additional medication; 1 Randomised Controlled 
Trial [RCT], n=104, attrition = 18.27%, relative risk [RR] 0.97 95% confidence 
interval [CI] 0.51, 1.84). 
 
Aripiprazole. One aripiprazole vs. placebo outcome (poor compliance) became 
equivocal after removing data from two trials with >50% attrition (33) (6 RCTs, 
n=1786, attrition = 30.24%, RR 0.74, CI 0.48, 1.13, no significant heterogeneity). 
However, because we could not establish from the review, the first author or from a 
related publication (39) what data from which study they used to calculate this 
outcome we were unsure if removing these trials was justified. The finding that 
people receiving aripiprazole were less likely to require extra antipsychotics 
remained significant (2 RCTs, n=573, attrition = 22.69%, RR 0.68, CI 0.54, 0.87, no 
significant heterogeneity) despite removal of data from two trials with >50% attrition 
(33). The remaining outcomes (‘relapse’ over short and medium term and needing 
extra benzodiazepines over a 24-hour period) were unaffected by excluding data 
with >50% attrition. 
 
Two aripiprazole outcomes (poor compliance and needing additional 
antipsychotics) were affected by removing data with >25% attrition. As already 
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discussed, we were not sure whether removing studies with >25% attrition was 
valid for the outcome of poor compliance. Doing so resulted in the removal of data 
from 6 trials. Based on the remaining data from 2 trials (40, 41), participants 
receiving intramuscular aripiprazole were no more likely to demonstrate poor 
compliance with the study protocol over 24 hours (2 RCTs, n=560, attrition=3.04%, 
RR 0.22 CI 0.03, 1.75, no significant heterogeneity) but were still less likely to need 
additional antipsychotics over a 24-hour period (1 RCT, n=263, attrition=2.28%, RR 
0.70 CI 0.54, 0.90) after removing data from three trials with >25% attrition (33, 
42). The treatment favourable findings regarding ‘relapse’ at 12 and 26 weeks and 
needing extra benzodiazepines over a 24-hour period were unaffected by 
excluding >25% attrition studies. 
 
Management of missing data and other methodological concerns 
 
Management of missing data. For intention-to-treat analysis of binary outcomes 
every review stated that they assumed people leaving early had the unfavourable 
outcome. This assumption could favour the active treatment when drop-out is 
higher in the placebo arm, as is the case for the majority of outcomes reported in 
the reviews. In reality, the reviews had to rely upon dichotomised continuous data 
which incorporated ‘last observation carried forward’ (LOCF) assumptions. Very 
few papers reported binary outcomes for only those who completed the trials, 
meaning the review authors could not complete sensitivity analyses to explore the 
impact of LOCF.  
 
Inappropriate exclusion of studies. All Cochrane reviews included a number of 
studies they said they had excluded, or intended to exclude, because of high levels 
of attrition. However the olanzapine, risperidone, amisulpride and aripiprazole 
reviews also excluded data from a number of other important studies with relatively 
low attrition because of missing standard deviations (SDs). They applied this rule to 
both continuous and binary data, although estimates of efficacy for the latter do not 
require SDs. In contrast, for continuous data Leucht and colleagues (13) inferred 
standard deviations from other measures of variance, such as p-values and t-
values, following procedures outlined in the current Cochrane Handbook (8).  
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Inappropriate inclusion of studies. The risperidone review included two very low-
attrition studies where all participants also received clozapine (37, 43). Both studies 
were negative for risperidone, in that those not receiving it faired significantly better 
on most outcomes. Their inclusion helps to explain the negative results of the 
Cochrane review and our own re-analysis above.  
 
Other issues. The risperidone review failed to extract all usable data from each 
study. For example, data on concomitant sedative use was published in ‘Potkin 
2006’ (44), data on average change in PANSS and CGI-S scores was published in 
‘Marder 1994b’ (36) and data on average change in PANSS scores was also 
published in ‘Marder 1994a’ (27). None of this data was included in the relevant 
outcome. 
 
INSERT TABLES 1 & 2 ABOUT HERE 
 
DISCUSSION 
 
Main findings 
 
Efficacy of second-generation antipsychotics at time of each review 
 
Quetiapine. Excluding studies with >50% attrition suggested there was little 
conclusive evidence, at the time the review was last updated, to determine the 
absolute efficacy of quetiapine in treating schizophrenia. This review included 
studies with more than 50% attrition, but did not appear to exclude other relevant 
studies. In their recent review of SGAs, Leucht and colleagues found quetiapine to 
have a small-moderate statistically significant effect over placebo in reducing 
PANSS/BPRS total scores, but the clinical significance of the difference was 
uncertain, the majority of included studies had over 50% drop-out and no difference 
in numbers achieving an important response was found (13). Whether newer low-
attrition studies will show quetiapine to be efficacious than placebo remains to be 
seen. Further analysis is clearly warranted.  
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Olanzapine. Although no data remained in the olanzapine Cochrane review after 
excluding high-attrition studies, this was a consequence of the review authors’ 
decision to exclude lower-attrition studies when no SDs were reported. Although a 
more comprehensive estimate of olanzapine efficacy is available from Leucht and 
colleagues (13), this is based on several studies with >50% attrition. The efficacy of 
olanzapine in studies with acceptable rates of drop-out requires further 
assessment.  
 
Risperidone. The risperidone review authors concluded the evidence for the 
efficacy of this drug is “unconvincing”. Such inferences cannot be made on the 
basis of their review, not least because it included several studies it should have 
excluded and excluded data from several studies it should have included. This, 
together with other problems, makes their results difficult to interpret. The review by 
Leucht and colleagues does not repeat these problems, but does include studies 
with unacceptable rates of attrition (13). As with olanzapine and quetiapine, further 
assessment of risperidone’s efficacy is clearly warranted.  
 
Amisulpride. Amisulpride was found to reduce total BPRS scores by around 7 
points, which is somewhat less than the 10 points thought to be required for 
minimal clinical improvement (45). According to both the Cochrane review and 
Leucht and colleagues, amisulpride also significantly reduced the risk of non-
response (13), however no response-rate data was available for studies with <25% 
drop-out.  
 
Aripiprazole. According to the Cochrane review and Leucht and colleagues (13), at 
12 and 26 weeks people taking aripiprazole were less likely to show at least 
minimal deterioration on the PANSS or CGI or were less likely to become 
moderately to severely uncooperative or hostile for 2 days (as rated by the relevant 
PANSS subscale) than those taking placebo. However whether this means 
aripiprazole prevents “impending relapse” (34) is debatable. Like most trials, 
participants stopped their previous antipsychotic treatment abruptly, meaning 
discontinuation-induced deterioration in the placebo group cannot be ruled out (46, 
47).  
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Unfortunately the Cochrane review also unnecessarily excluded a large amount of 
data because no SDs were supplied. The review by Leucht and colleagues again 
provides a more comprehensive assessment, but the figures they quote are again 
based on several studies with unacceptable rates of drop-out. The efficacy of 
aripiprazole in studies with acceptable completion rates remains unclear.   
 
Drop-out in clinical trials of antipsychotics. 
 
It is disconcerting that excluding studies with unacceptable rates of attrition often 
resulted in an absence of efficacy data for some of the most popular drugs in the 
world. It is also disconcerting that so many people leave these trials early. One 
possibility is that the high discontinuation rate for antipsychotics is restricted to a 
the artificial setting of clinical trials. However a recent analysis of the Norwegian 
Prescription Database found that, over a 20-month period, only 43% of almost 
9000 patients who picked up an initial antipsychotic prescription returned to pick up 
a second (48).  
 
High discontinuation rates can also be found in effectiveness trials of 
antipsychotics. In the government-funded CATIE study (Clinical Antipsychotic 
Trials of Intervention Effectiveness), 74% of participants discontinued their 
antipsychotic treatment over 18 months (49). In this study, olanzapine had the 
lowest proportion of people discontinuing treatment (64%) while quetiapine and 
risperidone had discontinuation rates of 82% and 74% respectively. According to 
the Cochrane reviews we examined, olanzapine had the highest discontinuation 
rates (approx. 52% to 91%) while risperidone had the lowest (approx. 25%). The 
more up-to-date review by Leucht and colleagues (13), who included data from an 
additional 2 trials (50, 51), found olanzapine had an overall discontinuation rate of 
only 36%, while only 29% and 38% discontinued early from risperidone and 
quetiapine treatment, respectively.  
 
Cochrane review methodology 
 
We found Cochrane reviews varied in their stated approach to handling attrition. 
This means that some drugs could be judged conservatively, while others could be 
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judged generously. Whether it is possible or desirable for the Cochrane 
Schizophrenia Group to prescribe how to deal with attrition is a matter for further 
debate. Reporting the specific proportion of data that is missing for each outcome 
could allow readers to have a greater understanding of the robustness of each 
finding.  
 
The assumptions that participants dropping out early have either an unchanged or 
unfavourable outcome could favour the active treatment group when placebo drop-
out is higher. However there is a heterogeneity of response to both antipsychotics 
and placebo (52) and in recovery generally (53-58). A potentially more reliable 
method of imputing missing summary binary data has been detailed by Higgins and 
colleagues (59) (see also 60, 61). The impact of assumptions about missing 
outcomes would be better understood if, as per the Cochrane Handbook, review 
authors were able to test whether their findings were robust to changing them (8; 
see sections 8.13 and 16). To allow this, and as recommended elsewhere (14), 
trialists need to also provide outcome data for only those who reach study endpoint 
as well as continue to follow-up participants who leave early.  
 
For continuous outcomes, the use of ‘last observation carried forward’ (LOCF) and 
‘completer-analysis’ (where only those providing endpoint data are included in the 
analysis) as the primary analysis should be avoided (10, 12, 14). These 
approaches create a serious risk of bias, particularly when drop-out is related to 
outcome (10) and varies substantially between groups (62, 63). Although more 
sophisticated ways of dealing with missing continuous data exist (for recent 
discussion see, e.g., 10, 12, 62, 63, 64), all require data normally unavailable to 
review authors (e.g., individual data or summary data for completers only). No 
approach is likely to produce credible results when more than half the summary 
outcome data is missing. 
 
Cochrane reviews are an important, valuable and relatively unbiased resource for 
researchers and clinicians hoping to improve treatments for people with a 
schizophrenia diagnosis. We stress that every review urged readers to exert great 
caution when interpreting their results. However it is likely that only readers familiar 
with the issues raised by missing data will appreciate how vulnerable the results 
 17 
actually are. The review authors were severely limited by the data provided in trial 
publications. Trialists, in turn, are faced with the challenge of avoiding substantial 
drop-out while meeting the various ethical obligations involved in conducting 
placebo-controlled trials. Thoughtful recommendations for improving the 
methodology and reporting of these trials have been proposed by Leucht and 
colleagues (14). As these authors argue, researchers must develop ways to 
continue to gather follow-up data from people who leave the double-blind process.  
 
Limitations 
 
We have not looked at comparisons of SGAs with other antipsychotics or examined 
the adverse effects of each SGA. The SGAs included here are generally accepted 
to be at least equivalent to first-generation drugs - both in terms of efficacy and 
tolerability (49, 65, 66). Although the issue of attrition is clearly relevant to these 
comparisons too (17) we did not investigate this here. 
 
Excluding high-attrition studies very often left only 1 or 2 small studies in the 
analysis. Clearly this greatly limits statistical power to detect effects, and a meta-
analysis of 1 study is not a meta-analysis. The relative absence of quality data from 
low-attrition studies is in itself remarkable for such popular drugs.  
 
For every SGA review studied, reported drop-out was significantly and consistently 
lower in treatment groups compared with placebo. We did not repeat this analysis. 
However it is uncertain whether drop-out is a reliable indicator of efficacy or 
tolerability. For example, whether the prominent subjective effects of antipsychotics 
(67, 68) lead to participant or rater unblinding (14, 69-71) and decreased treatment 
drop-out has not been investigated.  
 
New studies have been published since these reviews were completed. Other 
reviews may have approached the attrition issue differently and reached different 
conclusions. However our purpose was to review the findings of protocol-driven 
reviews currently accessible to service-users and clinicians. We focused on 
Cochrane reviews because they are likely to have had a major impact on 
healthcare policy in the UK and throughout the world over the last few years (7).  
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Our main finding was that the olanzapine, risperidone and aripiprazole Cochrane 
reviews misrepresented the available evidence on the efficacy of these drugs 
compared to placebo, the amisulpride and quetiapine reviews less so. Despite over 
15 years of research and widespread clinical use, we conclude that further analysis 
of the efficacy of these highly popular drugs in studies with acceptable rates of 
attrition is required. 
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Table 1. Overview of review standards and practice, focusing on attrition 
 
 Olanzapinea Risperidone Quetiapine  Amisulpride  Aripiprazole e 
Stated attrition cut-off for 
exclusion 
>50% >50% 
Formerly >50%. 
Currently no 
criterion. 
>40% >40% 
% leaving treatment early 
(any reason). 
0-6 weeks: 52.4% (206/393) 
0-6 months: 57% (80/140) 
52 weeks: 91.4% (181/198) 
25.5% 
(184/722) 
53.1% 
(271/510) 
Short term:  
18.5% (45/243)  
Med-long-term: 
44.9% (31/69) 
34.5%  
(613/1776) 
% leaving placebo early 
(any reason). 
0-6 weeks: 53.2% (109/205) 
0-6 months: 64.7% (22/34) 
52 weeks: 97% (66/68) 
37.5% 
(241/643) 
61.2% 
(126/206) 
Short term: 
36.2% (47/130)   
Med-long-term: 
68.1% (49/72) 
39.2%  
(317/809) 
% total leaving early in total 
(any reason). 
0-6 weeks: 52.7% (315/598) 
0-6 months: 58.6% (102/174) 
52 weeks: 92.9% (247/266) 
31.1% 
(425/1365) 
55.5% 
(397/716) 
Short term: 
24.7% (92/373)   
Med-long term: 
56.7% (80/141) 
35.98%  
(930/2585) 
Number of efficacy 
outcomes where missing 
data in both groups is 
above: 
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 Olanzapinea Risperidone Quetiapine  Amisulpride  Aripiprazole e 
20% 100% (17/17) 52.2% (12/23) 87.5% (7/8) 50% (4/8) 80% (4/5) 
30% 100% (17/17) 17.4% (4/23) 87.5% (7/8) 0% (0/8) 40% (2/5) 
40% 100% (17/17) 0% (0/23) 87.5% (7/8) 0% (0/8) 20% (1/5) 
50% 88.2% (17/17) 0% (0/23) 75% (6/8) 0% (0/8) 0% (0/5) 
60% 47.1% (8/17) 0% (0/23) 0% (0/8) 0% (0/8) 0% (0/5) 
70% 5.9% (1/17) 0% (0/23) 0% (0/8) 0% (0/8) 0% (0/5) 
Outcomes 
from  
original 
review:b  
Favouring 
placebo 
0% (0/13) 9.5% (2/21)d 0% (0/8) 0% (0/0) 0% (0/5) 
Null 
outcomes 
46.15% (6/13) 42.9% (9/21)d 37.5% (3/8) 16.6% (1/6) 0% (0/5) 
Favouring 
treatment 
53.85% (7/13) 47.6% (10/21)d 62.5% (5/8) 83.3% (5/6) 100% (5/5) 
Outcomes 
after 
Favouring 
placebo 
0% (0/0) 10% (2/20) 0% (0/5) 0% (0/6) 0% (0/5) 
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 Olanzapinea Risperidone Quetiapine  Amisulpride  Aripiprazole e 
excluding 
>50% 
attrition 
studies:b 
Null 
outcomes 
0% (0/0) 45% (9/20) 40% (2/5)c 16.6% (1/6) 20% (1/5) 
Favouring 
treatment 
0% (0/0) 45% (9/20) 60% (3/5)c 83.3% (5/6) 80% (4/5) 
Outcomes 
after 
excluding 
>25% 
attrition 
studies:b 
Favouring 
placebo 
0% (0/0) 35.3% (6/17) 0% (0/5)c 0% (0/1) 0% (0/5) 
Null 
outcomes 
0% (0/0) 41.2% (7/17) 40% (2/5)c 100% (1/1) 20% (1/5) 
Favouring 
treatment 
0% (0/0) 23.5% (4/17) 60% (3/5)c 0% (0/1) 80% (4/5) 
      
 
a Excludes outcomes from a clozapine discontinuation study with only very short-term (3-5 days) data (35).  
b Excluding outcomes not analysed by review authors because of skewed data. 
c All based on one 3-week study with 12 participants (38). 
d After fixing issues detailed in text. 
e Attrition reported here does not include participants who were withdrawn by the researchers when they showed at least minimal deterioration, as this was 
the primary outcome (34).  
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Table 2. Efficacy outcomes for risperidone vs placebo after fixing problems and excluding outcome data with >50% and 
>25% attrition. 
Outcomes once problems fixed Outcomes once >50% attrition excluded Outcomes once >25% attrition excluded 
No difference found No difference found No difference found 
20% reduction in PANSS total b 20% reduction in PANSS total b 20% reduction in PANSS total b 
4 RCTs, n=410, RR 0.64 [0.39, 1.04]a 3 RCTs, n=280, RR 0.66 [0.34, 1.28] a 1 RCT, n=68, RR 1.12 [0.87, 1.44] 
Difference between endpoint PANSS negative b Difference between endpoint PANSS negative b Difference between endpoint PANSS negative b 
4 RCTs, n=266, WMD -0.90 [-3.06, 1.27]a 3 RCTs, n=139, WMD -0.43 [-3.05, 2.19] a 2 RCTs, n=95, WMD 0.69 [-0.67, 2.05] 
Quality of life Quality of life Quality of life 
1 RCT, n=30, MD 0.80 [-5.43, 7.03] 1 RCT, n=30, MD 0.80 [-5.43, 7.03] 1 RCT, n=30, MD 0.80 [-5.43, 7.03] 
Difference between endpoint PANSS general b Difference between endpoint PANSS general b Mean change in PANSS negative b 
2 RCTs, n=74, WMD -5.00 [-20.37, 10.37] a 2 RCTs, n=74, WMD  -5.00 [-20.37, 10.37] a 1 RCT, n=223, MD -0.50 [-1.91, 0.91] 
Needing additional sedatives  Needing additional sedatives  20% and 30% PANSS total reduction combined b   
1 RCT, n=44, RR 0.87 [0.55, 1.36] 1 RCT, n=44, RR 0.87 [0.55, 1.36] 2 RCTs, n=294, RR 0.93 [0.61, 1.44] a 
Difference in CGI severity endpoint Difference in CGI severity endpoint 30% reduction in PANSS total b 
4 RCTs, n=266, WMD -0.29 [-1.18, 0.59]a 3 RCTs, n=139, WMD -0.08 [-1.14, 0.98] a 1 RCT, n=226, RR 0.75 [0.53, 1.07] 
Difference between endpoint PANSS total b Difference between endpoint PANSS total b 20% reduction in BPRS / PANSS total b 
4 RCTs, n=266, WMD -7.55 [-22.04, 6.95] a 3 RCTs, n=139, WMD  -3.84 [-19.05, 11.37] a 2 RCTs, n=291, RR  0.95 [0.63, 1.42] 
Difference between endpoint PANSS positive b Difference between endpoint PANSS positive b  
4 RCTS, n=266, WMD -2.23 [-7.12, 2.65] a 3 RCTs, n=139, WMD -0.99 [-6.05, 4.07] a Favours treatment 
Mean change in PANSS negative b Mean change in PANSS negative b Needing additional antipsychotics 
1 RCT, n=223, MD -0.50 [-1.91, 0.91] 1 RCT, n=223, MD -0.50 [-1.91, 0.91] 1 RCT, n=226, RR 0.61 [0.48, 0.78] 
  Mean change from CGI baseline 
Favours treatment Favours treatment 1 RCT, n=223, MD 0.70 [0.42, 0.98] 
No clinically significant improvement (CGI-S),  No clinically significant improvement (CGI-S),  Mean change in PANSS total b 
2 RCTs, n=329, RR 0.68 [0.46, 1.00] a 1 RCT, n=202, RR 0.80 [0.67, 0.97] a 1 RCT, n=223, MD -6.60 [-11.93, -1.27] 
Needing additional antipsychotics Needing additional antipsychotics Mean change in PANSS positive b 
 30 
1 RCT, n=226, RR 0.61 [0.48, 0.78] 1 RCT, n=226, RR 0.61 [0.48, 0.78] 1 RCT, n=223, MD -2.80 [-4.49, -1.11] 
Mean change from CGI baseline Mean change from CGI baseline  
1 RCT, n=223, MD 0.70 [0.42, 0.98] 1 RCT, n=223, MD 0.70 [0.42, 0.98] Favours placebo 
20% reduction in BPRS total b Mean change in PANSS total b Difference between endpoint PANSS delusions b   
2 RCTs, n=154, RR 0.54 [0.41, 0.71] 1 RCT, n=223, MD -6.60 [-11.93, -1.27] 1 RCT, n= 30, MD 0.70 [0.24, 1.16] 
Mean change in PANSS total b Mean change in PANSS positive b Difference in average endpoint score GAF 
1 RCT, n=223, MD -6.60 [-11.93, -1.27]   1 RCT, n=223, MD -2.80 [-4.49, -1.11] 1 RCT, n=30, MD -4.50 [-8.38, -0.62] 
Mean change in PANSS positive b 20% and 30% PANSS total reduction combined b   Difference between endpoint PANSS general b 
1 RCT, n=223, MD -2.80 [-4.49, -1.11] 5 RCTs, n=708, RR 0.75 [0.56, 0.99] a 1 RCT, n=30, MD 2.50 [0.03, 4.97] 
20% and 30% PANSS total reduction combined b   30% reduction in PANSS total b Difference in CGI severity endpoint 
6 RCTs, n=838, RR 0.71 [0.55, 0.92] a 2 RCTs, n=428, RR 0.78 [0.66, 0.92] 2 RCTs, n=95, WMD 0.50 [0.12, 0.88] 
30% reduction in PANSS total b 20% reduction in BPRS / PANSS total b Difference between endpoint PANSS total b 
2 RCTs, n=428, RR 0.78 [0.66, 0.92] 5 RCTs, n=705, RR 0.75 [0.56, 1.00] a 2 RCTs, n=95, WMD 5.54 [1.35, 9.73] 
20% reduction in BPRS / PANSS total b Difference between endpoint BPRS total b Difference between endpoint PANSS positive b 
7 RCTs, n=859, RR 0.68 [0.53, 0.88] a 1 RCT, n=44, MD -16.10 [-24.45, -7.75] 2 RCTs, n=95, WMD 2.30 [0.96, 3.64] 
Difference between endpoint BPRS total b   
2 RCTs, n=171, WMD -12.69 [-17.06, -8.32] Favours placebo Skewed 
 Difference between endpoint PANSS delusions b   Average depression scores b 
Favours placebo 1 RCT, n= 30, MD 0.70 [0.24, 1.16] Verbal working memory endpoint differences b 
Difference between endpoint PANSS delusions b   Difference in average endpoint score GAF  
1 RCT, n= 30, MD 0.70 [0.24, 1.16] 1 RCT, n=30, MD -4.50 [-8.38, -0.62] No data left 
Difference in average endpoint score GAF  No clinically significant improvement (CGI-S) 
1 RCT, n=30, MD -4.50 [-8.38, -0.62] Skewed 20% reduction in BPRS total b 
 Average depression scores b Difference between endpoint BPRS total b 
Skewed Verbal working memory endpoint differences b Needing additional sedatives  
Average depression scores b   
Verbal working memory endpoint differences b No data left  
 20% reduction in BPRS total b  
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PANSS=Positive and Negative Syndrome Scale; BPRS=Brief Psychiatric Rating Scale; CGI-S=Clinical Global Impression – Severity; GAF=Global Assessment of Functioning; 
RCT=Randomised Controlled Trial; RR=Relative Risk; MD=Mean Difference; WMD=Weighted Mean Difference. 95% Confidence Intervals for RR, MD or WMD are in 
parentheses. 
  
aSignificant heterogeneity in results. 
bPrimary outcomes (mental state) 
